Lebanon, United States
Adimab, founded in 2007, positions itself as a premier player in antibody discovery and engineering, serving as a favored partner within the biopharma sector. The company leverages a proprietary yeast-based platform, which facilitates the comprehensive discovery and optimization of human antibodies and other protein modalities, such as TCRs, with noted efficiency and precision. This technological advantage has positioned Adimab as a critical collaborator across the globe, especially with major pharmaceutical firms, innovative biotech companies, and leading academic institutions.
Since inception, Adimab has executed over 650+ discovery campaigns and contributed to the creation of 90+ clinical programs alongside more than 140 partners. By operating without an internal pipeline, the company fully dedicates its resources to the success of its partners' programs. The company's latest investment was a Venture - Series Unknown round on 01 January 2020. Headquartered in the United States, Adimab continues to drive innovation within the Biotechnology and Health Care sectors.
